naltrexone has been researched along with taurine in 229 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (7.86) | 18.2507 |
| 2000's | 116 (50.66) | 29.6817 |
| 2010's | 92 (40.17) | 24.3611 |
| 2020's | 3 (1.31) | 2.80 |
| Authors | Studies |
|---|---|
| Faden, AI; Graham, SH; Newman, A; Shimizu, H; Weinstein, P | 1 |
| Schuckit, MA | 1 |
| Litten, RZ | 1 |
| Overstreet, DH | 1 |
| Spanagel, R; Zieglgänsberger, W | 1 |
| Swift, RM | 1 |
| Drummond, DC; Moncrieff, J | 1 |
| Allen, JP; Litten, RZ | 2 |
| Gache, P; Siegrist, G | 1 |
| Bonn, D | 1 |
| Carey, TS; Crews, FT; Garbutt, JC; Lohr, KN; West, SL | 1 |
| Malerich, JA | 1 |
| Rueff, B | 1 |
| Mason, B | 1 |
| Farren, CK; O'Malley, SS | 1 |
| Cole, JC; Little, HJ; Littleton, JM | 1 |
| Fiellin, DA; O'Connor, PG; Reid, MC | 1 |
| Ait-Daoud, N; Johnson, BA | 1 |
| Hölter, SM; Spanagel, R | 1 |
| Koob, GF | 1 |
| Kalb, C | 1 |
| Brady, KT; Malcolm, R; Myrick, H | 1 |
| Mackler, SA; O'Brien, CP; Stromberg, MF; Volpicelli, JR | 1 |
| Boening, JA; Lesch, OM; Mason, BJ; Narita, M; Sinclair, D; Spanagel, R; Wiesbeck, GA; Wolffgramm, J | 1 |
| Tedeschi, M | 1 |
| Bean, P; Mattson, M | 1 |
| Carey, TS; Crews, FT; Garbutt, JC; Jackman, AM; Lohr, KN; Lux, LJ; Tolleson-Rinehart, S; West, SL | 1 |
| Gordon, SM | 1 |
| Korpi, E; Seppälä, T | 1 |
| Kranzler, HR; Van Kirk, J | 1 |
| Anton, RF | 1 |
| Yarborough, WH | 1 |
| Fideli, LP; Lejoyeux, M | 1 |
| Graham, R; Whelan, G; Wodak, AD | 1 |
| Boyeson, MG; Dixon, RM; Goodman, AM; Hameed, MH; Hulot, T; Hunter, JA; Mason, BJ; Wesnes, K | 1 |
| Baehr, M; Briken, P; Helwig, H; Holzbach, R; Jahn, H; Kämpf, P; Kiefer, F; Naber, D; Stracke, R; Tarnaske, T; Wiedemann, K | 1 |
| Mason, BJ | 3 |
| Heyser, CJ; Koob, GF; Moc, K | 1 |
| Bransberger, P; Crosse, S; Kranzler, HR; Mark, TL; Poole, VH; Song, X | 1 |
| Chambers, RA; Ciraulo, DA; Couper, D; Johnson, BA; O'Malley, SS; Roache, JD; Sarid-Segal, O | 1 |
| O'Brien, CP | 3 |
| Doran, CM; Fawcett, JE; Mattick, RP; Shakeshaft, AP; Shanahan, MD | 1 |
| Han, BD; Kim, MJ; Kim, SG; Park, JM; Stromberg, MF | 1 |
| Salaspuro, M | 1 |
| Littleton, J; Zieglgänsberger, W | 1 |
| Anton, RF; Swift, RM | 1 |
| Chick, J; Soyka, M | 1 |
| Amate, JM; Angeles, M; Bouza, C; Magro, A; Muñoz, A | 1 |
| Bespalov, A; Danysz, W; Kashkin, V; Malyshkin, A; Neznanova, O; Sukhotina, I; Zakharova, E | 1 |
| Anton, R; Myrick, H | 1 |
| Lee, TH | 1 |
| Kenna, GA; McGeary, JE; Swift, RM | 1 |
| Baltieri, DA; Castro, LA | 1 |
| Helwig, H; Jahn, H; Kiefer, F; Otte, C; Tarnaske, T; Wiedemann, K | 1 |
| Carai, MA; Colombo, G; Gessa, GL | 1 |
| Demiralay, C; Jahn, H; Kiefer, F; Otte, C; Wiedemann, K; Wolf, K | 1 |
| Jahn, H; Kiefer, F; Wiedemann, K | 1 |
| Berglund, M; Johnson, BA; Lesch, OM; Litten, RZ; Mann, K; Swift, RM; Willenbring, ML | 1 |
| Litten, RZ; Mattson, ME | 1 |
| Anton, R; Goldman, D; O'Malley, S; Oroszi, G | 1 |
| Pettinati, HM; Swift, R | 1 |
| Ait-Daoud, N; Johnson, BA; Roache, JD | 1 |
| Buonopane, A; Petrakis, IL | 1 |
| Williams, SH | 1 |
| Egli, M | 1 |
| Sher, L | 1 |
| Jahn, H; Kiefer, F; Naber, D; Otte, C; Wiedemann, K | 1 |
| Beilby, JJ; Doran, CM; Duszynski, KM; Mattick, RP | 1 |
| Egli, M; Heilig, M | 1 |
| Jung, YC; Namkoong, K | 1 |
| Anton, RF; Ciraulo, DA; Cisler, RA; Couper, D; Donovan, DM; Gastfriend, DR; Hosking, JD; Johnson, BA; LoCastro, JS; Longabaugh, R; Mason, BJ; Mattson, ME; Miller, WR; O'Malley, SS; Pettinati, HM; Randall, CL; Swift, R; Weiss, RD; Williams, LD; Zweben, A | 1 |
| Leeman, RF; Starosta, AN; Volpicelli, JR | 1 |
| Escher, T; Mittleman, G | 1 |
| Balester-Mouret, S; Batel, P | 1 |
| Bell, JR; Haber, PS; Morley, KC; Phung, N; Reid, SC; Richardson, K; Sannibale, C; Teesson, M; Thomson, C; Weltman, M | 1 |
| Pettinati, HM; Rabinowitz, AR | 1 |
| Kranzler, HR | 1 |
| Doggrell, SA | 1 |
| Bleich, S; Hillemacher, T; Kornhuber, J | 1 |
| Roesner, S; Soyka, M | 1 |
| Ducharme, LJ; Knudsen, HK; Roman, PM | 1 |
| Diehl, A; Mann, K | 1 |
| Mørland, J | 1 |
| Baer, JS; Forcehimes, AA; Kenna, GA; Miller, WR; Tonigan, JS | 1 |
| Quertemont, E; Tambour, S | 1 |
| Bray, JW; Cisler, RA; Couper, DJ; Kivlahan, DR; Martin, DJ; Miller, WR; Mitra, D; Zarkin, GA | 1 |
| Swift, R | 1 |
| Peterson, AM | 1 |
| McDonough, KP | 1 |
| Brunette, MF; Drake, RE; Green, AI; Noordsy, DL | 1 |
| Koeter, MW; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R | 1 |
| Andreoli, M; Ashby, CR; Gardner, EL; Heidbreder, CA; Hutcheson, DM; Marcon, C | 1 |
| Diehl, A; Jiménez-Arriero, MA; Kiefer, F; Klein, O; Rubio, G | 1 |
| Brunette, MF; Green, AI; Noordsy, DL; O'Keefe, C | 1 |
| Johnson, BA | 1 |
| Kuehn, BM | 1 |
| Lehert, P; Leucht, S; Rösner, S; Soyka, M | 1 |
| Anton, RF; Couper, D; Goldman, D; O'Malley, S; Oroszi, G; Pettinati, H; Swift, R | 1 |
| Burattini, C; Gass, JT; Griffin, WC; Janak, PH; Kinder, JR; McGeehan, AJ; Olive, MF | 1 |
| Berglund, M; Gorelick, D; Hesselbrock, V; Johnson, BA; Kranzler, HR; Möller, HJ; Soyka, M | 1 |
| Blanc, F; Perney, P; Rigole, H | 1 |
| Shea, CW | 1 |
| Giménez-Llort, L; Guitart-Masip, M; Hassankhali, H; Johansson, B; Landgren, S; Lindholm, J; Nicoleau, C; Ogren, SO; Terenius, L | 1 |
| Baillie, A; Haber, P; Morley, K; Reid, S; Richardson, K; Sannibale, C; Teesson, M; Weltman, M | 1 |
| Bowers, TG; Snyder, JL | 1 |
| Ciraulo, D; Cox, CE; Gorroochurn, P; Mattson, ME; Pettinati, HM; Weiss, RD; Youngblood, M; Zweben, A | 1 |
| Abernathy, KE; Bartlett, SE; Chandler, LJ; Medina, B; Simms, JA; Steensland, P; Wise, R | 1 |
| Soyka, M | 2 |
| Kassed, CA; Kranzler, HR; Levit, KR; Mark, TL; Vandivort-Warren, R | 1 |
| Aldridge, A; Bray, JW; Cisler, RA; Couper, DJ; Mills, MJ; Mitra, D; Zarkin, GA | 1 |
| Hosking, JD; Locastro, JS; O'malley, SS; Swift, R; Weiss, RD | 1 |
| Garbutt, JC | 1 |
| Diehl, A; Herre, H; Kiefer, F; Mann, K; Mutschler, J; Vollmert, C | 1 |
| Czachowski, CL; Delory, MJ | 1 |
| Gann, H; Heinz, A; Kiefer, F; Mann, K; Smolka, M; Wellek, S | 1 |
| Boakes, R; Colagiuri, B; Haber, P; Morley, K | 1 |
| Kenna, GA; Leggio, L; Ray, LA; Swift, RM | 1 |
| Daoust, M; Houchi, H; Koeter, MW; Naassila, M; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R | 1 |
| Rösner, S; Soyka, M | 2 |
| de Silva, V; Hanwella, R | 1 |
| Oslin, DW; Ray, LA | 1 |
| Couper, D; Donovan, D; Gueorguieva, R; Krystal, JH; O'Malley, SS; Rounsaville, BJ; Wu, R | 3 |
| Abraham, AJ; Knudsen, HK; Roman, PM; Rothrauff, TC | 1 |
| Olive, MF | 1 |
| Bray, JW; Dunlap, LJ; Kivlahan, DR; Latham, P; McKay, JR; Mills, M; Tonigan, JS; Zarkin, GA | 1 |
| Bowe, T; Harris, AH; Humphreys, KN; Kivlahan, DR | 1 |
| Aldridge, A; Bray, JW; Cisler, RA; Couper, D; McKay, JR; Mills, M; O'Malley, S; Zarkin, GA | 1 |
| Grosshans, M; Kiefer, F; Kobiella, A; Mutschler, J | 1 |
| Greenfield, SF; O'Malley, S; Pettinati, HM; Randall, CL; Randall, PK | 1 |
| Falk, D; Fertig, J; Johnson, B; Litten, RZ; Liu, L; Mattson, M; Ryan, M; Stout, R; Wang, XQ | 1 |
| Longabaugh, R; O'Malley, SS; Wirtz, PW; Zywiak, WH | 1 |
| Capone, C; Kahler, CW; O'Malley, SS; Swift, RM | 1 |
| Bowen, S; Donovan, DM; Witkiewitz, K | 1 |
| Chalk, M; Gastfriend, DR; Kranzler, HR; Mark, TL; Montejano, LB | 1 |
| Alam, DA; Martorana, A | 1 |
| Abraham, AJ; Knudsen, HK; Roman, PM | 1 |
| Donovan, D; Hartzler, B; Villarroel, N; Witkiewitz, K | 1 |
| Baser, O; Chalk, M; Gastfriend, DR; Rawson, R | 1 |
| Campanella, S; Kornreich, C; Noel, X; Petit, G; Verbanck, P | 1 |
| Godinho, A; Mohapatra, S; Patra, J; Popova, S; Rehm, J; Schwappach, D | 1 |
| Lumbad, J; Yancey, JR | 1 |
| Krogh, J; Nordentoft, M; Petrov, I | 1 |
| Bujarski, S; Courtney, KE; Ray, LA; Squeglia, LM | 1 |
| Hunter-Reel, D; Witkiewitz, K; Zweben, A | 1 |
| Doran, CM; Navarro, HJ; Petrie, DJ; Shakeshaft, A | 1 |
| Spanagel, R; Vengeliene, V | 1 |
| Book, SW; Miller, PM; Stewart, SH | 1 |
| Chen, J; Isaac, M; Johnson, BA; Liu, L; O'Quigley, J; Wang, XQ; Zhang, D | 1 |
| Fucito, LM; Gueorguieva, RV; Gulliver, SB; Mattson, ME; O'Malley, SS; Park, A | 1 |
| Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ | 1 |
| Clark, DB | 1 |
| Bühler, KM; Echeverry-Alzate, V; Giné, E; Gorriti, MÁ; Huertas, E; López-Moreno, JA; Olmos, P; Rodríguez de Fonseca, F; Santos, Á; Tuda-Arízcun, M | 1 |
| Gahr, M; Kölle, MA; Schönfeldt-Lecuona, C | 1 |
| Blodgett, JC; Finney, JW; Humphreys, K; Maisel, NC; Wilbourne, PL | 1 |
| Anton, RF; Batra, A; Berner, M; Heinz, A; Hermann, D; Hoffmann, S; Kiefer, F; Lemenager, T; Mann, K; Reinhard, I; Smolka, MN; Wellek, S; Wodarz, N; Zimmermann, US | 1 |
| Bujarski, S; Lunny, K; O'Malley, SS; Ray, LA | 1 |
| Bowe, T; Ellerbe, L; Gordon, AJ; Hagedorn, H; Harris, AHS; Kivlahan, D; Lembke, A; Oliva, E; Reeder, RN; Trafton, JA | 1 |
| Agovic, MS; Banerjee, SP; Chan, CY; Friedman, E; Jashanmal, I; Ragnauth, A; Sostris, V; Vidal, L | 1 |
| Choi, IG; Kang, TC; Kim, JW; Lee, BC | 1 |
| Donovan, D; Gueorguieva, R; Krystal, JH; O'Malley, SS; Wu, R | 1 |
| Anton, RF; Baker, NL; Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ; Randall, PK | 1 |
| O'Connor, PG; O'Malley, SS | 1 |
| Krishnan-Sarin, S; Krystal, JH; O'Malley, S | 1 |
| Franck, J; Jayaram-Lindström, N | 1 |
| Falk, D; Fertig, J; Litten, RZ; Ryan, M | 1 |
| Castle, IJ; Chen, CM; Falk, D; Fertig, J; Litten, RZ; Ryan, M; Yi, HY | 1 |
| Heinz, A; Müller, CA | 1 |
| Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R | 1 |
| DeSantis, SM; Zhu, H | 1 |
| Liang, J; Olsen, RW | 1 |
| Braciszewski, JM; Falk, D; Kranzler, HR; O'Malley, SS; Stout, RL; Subbaraman, MS | 1 |
| Friedmann, PD; Park, TW | 1 |
| Oetzel, S | 1 |
| Anton, RF; Book, SW; Schacht, JP | 1 |
| Goutier, W; Kloeze, M; McCreary, AC | 1 |
| Fucito, LM; Gueorguieva, R; Hoffmann, S; Mann, K; O'Connor, PG; O'Malley, SS; Weisner, C; Wu, R | 1 |
| Borro, P; Leone, S; Testino, G | 1 |
| Amato, RJ; Hulin, MW; Lawrence, MN; Weed, PF; Winsauer, PJ | 1 |
| Donoghue, K; Drummond, C; Elzerbi, C; Pilling, S; Saunders, R; Whittington, C | 1 |
| Saitz, R | 1 |
| Lieb, M; Soyka, M | 1 |
| Frohe, T; Kirouac, M; Maisto, SA; McCallion, E; Vowles, KE; Witkiewitz, K | 1 |
| Chalk, M; Lubran, R; Mark, TL; McCance-Katz, EF; Richardson, J | 1 |
| Agabio, R; Franconi, F; Gessa, GL; Pani, PP; Preti, A | 1 |
| Gofman, AG; Ponizovskiy, PA | 1 |
| Higuchi, S; Yumoto, Y | 1 |
| Helton, SG; Lohoff, FW | 1 |
| Anton, RF; Fitzmaurice, GM; Griffin, ML; McHugh, RK; Weiss, RD | 1 |
| Houck, J; Longabaugh, R; Miller, WR; Moyers, TB; Rice, SL | 1 |
| Creedon, TB; Hodgkin, D; Horgan, CM; Matteucci, AM; Reif, S; Stewart, MT | 1 |
| Cicin-Šain, L; Kovak-Mufić, A; Marušić, S; Matošić, A; Vidrih, B | 1 |
| Baillie, A; Haber, PS; Logge, W; Morley, KC; Pearson, SA | 2 |
| Salisbury-Afshar, E | 1 |
| Bramness, JG; Mann, K; Wurst, FM | 1 |
| Mann, K; Roos, CR; Witkiewitz, K | 1 |
| Bowe, T; Christopher, M; Finlay, AK; Gidwani, R; Hagedorn, H; Harris, AH; Kay, C; Nevedal, A; Rosen, C | 1 |
| Crits-Christoph, P; Gallop, R; Gastfriend, DR; Gibbons, MB; Lundy, C; Markell, HM; Stringer, M | 1 |
| Metrik, J; Patterson, D; Subbaraman, MS; Swift, R | 1 |
| Brewer, C; Skinner, M; Streel, E | 1 |
| Goh, ET; Morgan, MY | 1 |
| Manolopoulos, VG; Ragia, G | 1 |
| Bowe, TR; Burden, JL; Ellerbe, LS; Finlay, AK; Gupta, S; Harris, AHS; Rubinsky, AD; Timko, C; Wong, JJ | 1 |
| Gomes, T; Martins, D; Singh, S; Spithoff, S; Turner, S | 1 |
| Hallgren, KA; Heather, N; Kirouac, M; Maisto, SA; Montes, KS; Pearson, MR; Roos, CR; Wilson, AD; Witkiewitz, K | 1 |
| Lyon, J | 1 |
| Barkley-Levenson, A; Crabbe, JC; Hack, WR; Huang, LC; Metten, P; Ozburn, AR; Schlumbohm, JP; Spence, SE | 1 |
| Ericson, M; Lidö, HH; Söderpalm, B | 1 |
| Bonnet, U; Dembski, N; Niederhofer, A; Niederhofer, E; Nyhuis, PW; Scherbaum, N; Schifano, F; Specka, M; Tenbergen, M | 1 |
| Hughes, JR; Klemperer, EM; Naud, S | 1 |
| Kranzler, HR; Soyka, M | 1 |
| Anton, R; Batzler, A; Biernacka, JM; Colby, C; Coombes, BJ; Frank, J; Geske, JR; Goldman, D; Ho, AM; Ho, MF; Hodgkinson, C; Karpyak, VM; Kiefer, F; Mann, K; O'Malley, SS; Pozsonyiova, S; Rietschel, M; Skime, M; Weinshilboum, R; Zillich, L | 1 |
| Gomes, T; Konstantelos, N; Lecce, P; McCormack, D; Tadrous, M; Tourchian, N | 1 |
92 review(s) available for naltrexone and taurine
| Article | Year |
|---|---|
Recent developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Anti-Anxiety Agents; Buspirone; Disulfiram; Ethanol; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Taurine | 1996 |
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans; Naltrexone; Narcotic Antagonists; Neurons; Rats; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Recurrence; Substance Withdrawal Syndrome; Synaptic Transmission; Taurine | 1997 |
The pharmacological treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depression; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine | 1997 |
Advances in development of medications for alcoholism treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Drug Therapy, Combination; Humans; Naltrexone; Taurine | 1998 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl Acetate; Naltrexone; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 1999 |
Pharmacological treatment of alcohol dependence: a review of the evidence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Lithium; Naltrexone; Narcotic Antagonists; Serotonin Agents; Taurine | 1999 |
[Evaluation of drug treatment of primary alcoholism].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Self-Help Groups; Taurine; Treatment Outcome | 1999 |
New therapies for alcohol problems: application to primary care.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Primary Health Care; Psychotherapy; Research Design; Taurine; United States | 2000 |
Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Receptors, N-Methyl-D-Aspartate; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine | 2000 |
Animal models of craving for ethanol.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Disease Models, Animal; Drug Tolerance; Motivation; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Rats; Reinforcement, Psychology; Reproducibility of Results; Substance Withdrawal Syndrome; Taurine | 2000 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carbamazepine; Drug Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Ritanserin; Serotonin Agents; Sodium Oxybate; Substance Withdrawal Syndrome; Taurine; Valproic Acid; Vigabatrin | 2001 |
Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Humans; Naltrexone; Narcotic Antagonists; Prosencephalon; Rats; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Serotonin Agents; Taurine | 2001 |
Naltrexone and acamprosate. Using new drugs for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Australia; Clinical Trials as Topic; Female; Guidelines as Topic; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Satisfaction; Prognosis; Taurine; Treatment Outcome | 2001 |
Pharmacotherapy for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Health Policy; Humans; Lithium; Naltrexone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; United States | 1999 |
[Alcohol--mechanism of action, interactions and treatment of alcohol abuse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine | 1998 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome | 2001 |
Pharmacologic approaches to the management of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Clinical Trials as Topic; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2001 |
[Long-term treatment of alcohol dependance].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Disulfiram; Family Therapy; Humans; Long-Term Care; Naltrexone; Psychotherapy; Self-Help Groups; Social Support; Social Work; Taurine; Treatment Outcome | 2002 |
New pharmacotherapies for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Self-Help Groups; Taurine; Treatment Outcome | 2002 |
Acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Double-Blind Method; Humans; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2003 |
Research advances in the understanding and treatment of addiction.
Topics: Acamprosate; Alcohol Deterrents; Brain; Chronic Disease; Disease Progression; Humans; Naltrexone; Narcotics; Prognosis; Recurrence; Risk Factors; Substance-Related Disorders; Taurine | 2003 |
Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine | 2003 |
[Drug therapy of alcohol dependence--a critical review].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Fructose; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Topiramate | 2003 |
Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Brain; Humans; Naltrexone; Narcotic Antagonists; Receptors, Glutamate; Recurrence; Taurine | 2003 |
Current pharmacotherapies of alcoholism: a U.S. perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Receptors, Glutamate; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine; United States | 2003 |
Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Europe; Humans; Meta-Analysis as Topic; Naltrexone; Narcotic Antagonists; Placebos; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Taurine; Treatment Outcome | 2003 |
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2004 |
Recent advances in the pharmacotherapy of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Taurine; Topiramate | 2004 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Clinical Trials as Topic; Disulfiram; Excitatory Amino Acid Antagonists; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Combining treatments for alcoholism: why and how?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Taurine | 2005 |
COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Topics: Acamprosate; Alcohol Dehydrogenase; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Therapy; Drug Therapy; Genetic Markers; Genotype; Haplotypes; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Psychotherapy; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Taurine | 2005 |
Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2005 |
Pharmacotherapy of alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amitriptyline; Antidepressive Agents, Tricyclic; Comorbidity; Disulfiram; Dopamine; Drug Interactions; Ethanol; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Male; Mental Disorders; Naltrexone; Narcotics; Serotonin; Taurine | 2005 |
Medications for treating alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Disulfiram; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; Treatment Outcome | 2005 |
Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Naltrexone; Rodentia; Taurine | 2005 |
Alcoholism and suicidal behavior: a clinical overview.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Tricyclic; Anxiety; Comorbidity; Depressive Disorder, Major; Humans; Hydroxyindoleacetic Acid; Naltrexone; Narcotic Antagonists; Personality Disorders; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Suicide; Suicide, Attempted; Taurine | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate | 2006 |
Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; gamma-Aminobutyric Acid; Glutamine; Humans; Models, Biological; Models, Neurological; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Neurons; Polymorphism, Genetic; Receptors, Opioid, mu; Recurrence; Taurine | 2006 |
Choosing the right medication for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Choice Behavior; Cognitive Behavioral Therapy; Combined Modality Therapy; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate | 2006 |
[Neurobiological mechanisms and pharmacological treatment options for alcohol craving].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Neurotransmitter Agents; Receptors, Glutamate; Taurine | 2007 |
New pharmacological approaches for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Secondary Prevention; Taurine; Topiramate | 2006 |
Trends in the adoption of medications for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Longitudinal Studies; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine; United States | 2006 |
[Pharmacological relapse prevention in alcohol and tobacco dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Taurine; Tobacco Use Disorder | 2007 |
Preclinical and clinical pharmacology of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Dopamine; GABA Modulators; Glutamic Acid; Humans; Naltrexone; Narcotic Antagonists; Serotonin; Taurine | 2007 |
Emerging approaches to managing alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Brain; Disulfiram; Drug Therapy, Combination; Ethanol; Humans; Naltrexone; Taurine | 2007 |
Improving adherence in patients with alcohol dependence: a new role for pharmacists.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Disulfiram; Humans; Naltrexone; Patient Compliance; Pharmacists; Professional Role; Taurine; Treatment Refusal | 2007 |
Substance abuse and schizophrenia: pharmacotherapeutic intervention.
Topics: Acamprosate; Alcohol Deterrents; Antipsychotic Agents; Clozapine; Disulfiram; Drug Interactions; Humans; Naltrexone; Narcotics; Schizophrenia; Substance-Related Disorders; Taurine | 2008 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2008 |
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Publication Bias; Secondary Prevention; Taurine | 2008 |
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Disulfiram; Fructose; Health Planning Guidelines; Humans; Naltrexone; Ondansetron; Societies, Scientific; Substance-Related Disorders; Taurine; Topiramate | 2008 |
[Alcohol dependence: diagnosis and treatment].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Disulfiram; Humans; Motivation; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine | 2008 |
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Single-Blind Method; Taurine | 2008 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate | 2009 |
[Recent results in relaps prevention of alcoholism with Disulfiram].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Aldehyde Dehydrogenase; Combined Modality Therapy; Disulfiram; Drug Interactions; Drug Therapy, Combination; Germany; Humans; Metabolic Clearance Rate; Motivation; Naltrexone; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine | 2008 |
Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Receptors, Opioid; Secondary Prevention; Taurine; Temperance; Ventral Tegmental Area | 2008 |
Addiction treatment: level of care determination.
Topics: Acamprosate; Alcohol Deterrents; Behavior Therapy; Cognitive Behavioral Therapy; Health Status Indicators; Humans; Inpatients; Mass Screening; Naltrexone; Narcotic Antagonists; Outpatients; Primary Health Care; Substance-Related Disorders; Taurine | 2011 |
How cognitive assessment through clinical neurophysiology may help optimize chronic alcoholism treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognition; Humans; Naltrexone; Psychotherapy; Taurine | 2011 |
Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
Topics: Acamprosate; Alcoholism; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Naltrexone; Taurine; Treatment Outcome | 2012 |
Opioid antagonists for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine; Treatment Outcome | 2011 |
[Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Evidence-Based Medicine; Humans; Naltrexone; Taurine; Treatment Outcome | 2011 |
New pharmacological treatment strategies for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Disulfiram; Drugs, Investigational; History, 18th Century; History, 21st Century; Humans; Naltrexone; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine | 2013 |
Medical treatment of alcohol dependence: a systematic review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Off-Label Use; Taurine; Topiramate; Treatment Outcome | 2011 |
[Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Middle Aged; Naltrexone; Secondary Prevention; Taurine; Treatment Outcome | 2013 |
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Ethanol; Humans; Inactivation, Metabolic; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Time Factors; Treatment Outcome | 2013 |
The current situation of treatment systems for alcoholism in Korea.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Benzodiazepines; Humans; Naltrexone; Psychotherapy; Republic of Korea; Taurine | 2013 |
Medications for unhealthy alcohol use: across the spectrum.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Disulfiram; Dopamine Agents; Fructose; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2011 |
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain Chemistry; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2008 |
Pharmacotherapy for alcohol dependence: status of current treatments.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Taurine | 2013 |
Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Biomedical Research; Drug Industry; Health Services Needs and Demand; Humans; Insurance, Health, Reimbursement; Naltrexone; Narcotic Antagonists; Taurine | 2014 |
The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebo Effect; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2013 |
[New treatment options for alcohol dependence].
Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate | 2013 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; Randomized Controlled Trials as Topic; Taurine; Topiramate | 2014 |
A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bayes Theorem; Humans; Naltrexone; Randomized Controlled Trials as Topic; Review Literature as Topic; Taurine | 2014 |
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Benzodiazepines; Disulfiram; Ethanol; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Plant Preparations; Receptors, GABA-A; Taurine; Topiramate | 2014 |
Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.
Topics: Acamprosate; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Directive Counseling; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Substance-Related Disorders; Taurine; United States | 2014 |
Pharmacologic treatment of alcoholism.
Topics: Acamprosate; Alcoholism; Animals; Brain; Humans; Naltrexone; Nerve Net; Neuroimaging; Pharmacogenetics; Taurine; Valproic Acid | 2014 |
Treatment of alcohol dependence: recent progress and reduction of consumption.
Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking; Contraindications; Craving; Disulfiram; Drugs, Investigational; Europe; Humans; Meta-Analysis as Topic; Multicenter Studies as Topic; Naltrexone; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Sodium Oxybate; Taurine | 2014 |
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Europe; Female; Global Health; Humans; Male; Middle Aged; Naltrexone; Randomized Controlled Trials as Topic; Recurrence; Taurine; Treatment Outcome | 2015 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline | 2015 |
Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Benzodiazepines; Disulfiram; Female; Humans; Male; Naltrexone; Sex Factors; Taurine; Treatment Outcome | 2016 |
[Depression in alcohol addicted patients].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depressive Disorder; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Taurine | 2015 |
[Pharmacological therapies for alcohol use disorder in Japan].
Topics: Acamprosate; Alcohol-Related Disorders; Alcohols; Humans; Japan; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2015 |
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Disulfiram; Fructose; Humans; Naltrexone; Pharmacogenetics; Precision Medicine; Taurine; Topiramate; United States | 2015 |
NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain; Disulfiram; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Minisatellite Repeats; Monoamine Oxidase; Naltrexone; Narcotic Antagonists; Neuropeptide Y; Norepinephrine; Ondansetron; Polymorphism, Genetic; Serotonin; Synaptic Transmission; Taurine | 2016 |
Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bioethical Issues; Disulfiram; Humans; Naltrexone; Taurine | 2017 |
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome | 2017 |
Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine; Taurine | 2017 |
The Glycine Receptor-A Functionally Important Primary Brain Target of Ethanol.
Topics: Acamprosate; Alcohol Drinking; Animals; Brain; Dopamine; Ethanol; Humans; Naltrexone; Receptors, Glycine; Taurine | 2017 |
Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taurine; Treatment Outcome | 2018 |
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Disulfiram; Humans; Naltrexone; Taurine | 2018 |
[Pharmacotherapy of alcohol withdrawal: update and new developments].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Germany; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2021 |
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.
Topics: Alcohol Deterrents; Alcoholism; Female; Genome-Wide Association Study; Humans; Male; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Taurine; Treatment Outcome | 2021 |
43 trial(s) available for naltrexone and taurine
| Article | Year |
|---|---|
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome | 2001 |
A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.
Topics: Acamprosate; Adolescent; Adult; Alcohol Deterrents; Alcoholism; Brain; Cognition; Double-Blind Method; Drug Interactions; Drug Tolerance; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Reaction Time; Taurine | 2002 |
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.
Topics: Acamprosate; Alcoholism; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Secondary Prevention; Taurine; Treatment Outcome | 2003 |
Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.
Topics: Acamprosate; Adult; Alcoholism; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Neuropsychological Tests; Taurine | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine | 2003 |
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.
Topics: Acamprosate; Adult; Alcoholism; Behavior Therapy; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Middle Aged; Naltrexone; Pilot Projects; Taurine | 2003 |
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Depression; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotics; Predictive Value of Tests; Prospective Studies; Secondary Prevention; Somatoform Disorders; Surveys and Questionnaires; Taurine; Treatment Outcome | 2005 |
Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Leptin; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Recurrence; Taurine | 2005 |
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
Topics: Acamprosate; Adrenocorticotropic Hormone; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Taurine; Time Factors | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebo Effect; Taurine | 2006 |
Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety; Australia; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Secondary Prevention; Taurine; Treatment Outcome | 2006 |
Psychometrics of the Drinker Inventory of Consequences (DrInC).
Topics: Acamprosate; Alcoholism; Combined Modality Therapy; Factor Analysis, Statistical; Follow-Up Studies; Humans; Naltrexone; Narcotic Antagonists; Psychometrics; Psychotherapy; Surveys and Questionnaires; Taurine | 2007 |
Measuring economic outcomes of alcohol treatment using the Economic Form 90.
Topics: Absenteeism; Acamprosate; Accidents, Traffic; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Criminal Law; Employment; Female; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Male; Middle Aged; Models, Economic; Naltrexone; Prisons; Taurine; Treatment Outcome; United States | 2007 |
The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
Topics: Acamprosate; Affect; Alcohol Deterrents; Alcoholism; Autonomic Nervous System; Cues; Double-Blind Method; Galvanic Skin Response; Heart Rate; Humans; Hydrocortisone; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Patient Compliance; Psychiatric Status Rating Scales; Surveys and Questionnaires; Taurine | 2007 |
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Topics: Acamprosate; Adult; Alcoholism; Alleles; Amino Acid Substitution; Asparagine; Aspartic Acid; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Genetic Carrier Screening; Genetic Markers; Genotype; Homozygote; Humans; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Prognosis; Receptors, Opioid, mu; Taurine; Temperance; Treatment Outcome | 2008 |
Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Taurine; Treatment Outcome | 2008 |
Relationship between medication adherence and treatment outcomes: the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Taurine; Temperance; Treatment Outcome; United States | 2008 |
Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Taurine; Temperance | 2008 |
Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Negativism; Placebo Effect; Secondary Prevention; Taurine; Temperance; Treatment Outcome | 2008 |
Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Dopamine Agents; Double-Blind Method; Excitatory Amino Acid Agents; Female; Germany; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Psychotherapy; Reflex; Taurine; United States; Young Adult | 2009 |
Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Blood Glucose; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Taurine | 2009 |
Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Cues; Female; Genotype; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Receptors, Dopamine D2; Receptors, GABA-A; Receptors, Opioid, mu; Taurine; Treatment Outcome | 2009 |
Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Black or African American; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2009 |
[Impact of functional social support for abstinence after inpatient detoxification].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Prognosis; Prospective Studies; Psychotherapy, Group; Retreatment; Secondary Prevention; Social Support; Surveys and Questionnaires; Taurine | 2010 |
Network support as a prognostic indicator of drinking outcomes: the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Prognosis; Social Support; Taurine; Temperance; Treatment Outcome | 2010 |
Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Family; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Sex Characteristics; Substance-Related Disorders; Taurine; Treatment Outcome | 2011 |
Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Taurine; Temperance | 2011 |
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2011 |
Self-efficacy change as a mediator of associations between therapeutic bond and one-year outcomes in treatments for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Professional-Patient Relations; Self Efficacy; Taurine; Treatment Outcome | 2011 |
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Taurine; Temperance; Treatment Outcome | 2012 |
Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders?
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Forecasting; Humans; Male; Middle Aged; Naltrexone; Social Support; Spouses; Taurine; Treatment Outcome | 2012 |
The cost-effectiveness of tailored, postal feedback on general practitioners' prescribing of pharmacotherapies for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Alcoholism; Cost-Benefit Analysis; Female; General Practitioners; Humans; Male; Naltrexone; New South Wales; Postal Service; Practice Patterns, Physicians'; Taurine | 2012 |
Trajectory analyses in alcohol treatment research.
Topics: Acamprosate; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Algorithms; Behavior Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Double-Blind Method; Female; Fructose; Humans; Linear Models; Male; Middle Aged; Models, Statistical; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Nonlinear Dynamics; Regression Analysis; Research; Research Design; Taurine; Topiramate; Treatment Outcome; Young Adult | 2012 |
Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Smoking; Taurine; Treatment Outcome | 2012 |
Simultaneous modeling of the impact of treatments on alcohol consumption and quality of life in the COMBINE study: a coupled hidden Markov analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Humans; Markov Chains; Naltrexone; Quality of Life; Taurine; Treatment Outcome | 2012 |
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Counseling; Disease-Free Survival; Double-Blind Method; Female; Germany; Hospitalization; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Placebos; Randomized Controlled Trials as Topic; Research Design; Taurine; Treatment Outcome; United States | 2013 |
The effects of drinking goal on treatment outcome for alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Goals; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Recurrence; Taurine; Treatment Outcome | 2013 |
Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Disease Progression; Female; Humans; Longitudinal Studies; Male; Models, Statistical; Naltrexone; Narcotic Antagonists; Poisson Distribution; Risk-Taking; Taurine; Temperance; Treatment Outcome | 2013 |
What happens when people discontinue taking medications? Lessons from COMBINE.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Naltrexone; Patient Dropouts; Recurrence; Taurine | 2014 |
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therapy; Chronic Pain; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Pain Measurement; Recurrence; Taurine; Treatment Outcome | 2015 |
Therapist empathy, combined behavioral intervention, and alcohol outcomes in the COMBINE research project.
Topics: Acamprosate; Adaptation, Psychological; Affect; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Empathy; Health Personnel; Humans; Middle Aged; Naltrexone; Taurine; Treatment Outcome | 2016 |
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Reproducibility of Results; Reward; Taurine; Treatment Outcome | 2017 |
Effectiveness of Psychoanalytic-Interactional Group Therapy vs. Behavioral Group Therapy in Routine Outpatient Treatment of Alcohol-Dependent Patients.
Topics: Acamprosate; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; Outpatients; Psychoanalytic Therapy; Psychotherapy, Group; Recurrence; Secondary Prevention; Taurine; Treatment Outcome | 2018 |
95 other study(ies) available for naltrexone and taurine
| Article | Year |
|---|---|
Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia.
Topics: Animals; Aspartic Acid; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Glycine; Hippocampus; Ischemic Attack, Transient; Kinetics; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Reperfusion; Stereoisomerism; Taurine; Time Factors | 1993 |
International update: new findings on promising medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Cocaine; Comorbidity; Europe; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Taurine; United States | 1996 |
Alternatives to naltrexone in animal models.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Haplorhini; Humans; Naltrexone; Narcotic Antagonists; Rats; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine; Thyrotropin-Releasing Hormone | 1996 |
New drug treatments for alcohol problems: a critical appraisal.
Topics: Acamprosate; Alcoholism; Anti-Anxiety Agents; Buspirone; Dopamine Antagonists; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Taurine | 1997 |
[Medical treatment of alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine | 1998 |
New treatments for alcohol dependency better than old.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Taurine | 1999 |
Prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Self-Help Groups; Taurine | 1999 |
Medical allies against alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine | 1999 |
Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychiatry); Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine | 1999 |
Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze.
Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Central Nervous System Depressants; Ethanol; Exploratory Behavior; Male; Mice; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2000 |
Pharmacological validation of a new animal model of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Reproducibility of Results; Secondary Prevention; Self Administration; Substance Withdrawal Syndrome; Taurine | 2000 |
Can this pill stop you from hitting the bottle?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Humans; Motivation; Naltrexone; Narcotic Antagonists; Taurine; United States | 2001 |
Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Taurine | 2001 |
Combined behavioral and pharmacologic treatments of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine | 2001 |
Does the alcoholic's remedy come in a pill?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Excitatory Amino Acid Antagonists; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Ondansetron; Patient Compliance; Serotonin Antagonists; Social Support; Taurine; United States | 2001 |
Addiction medicine for the primary care physician.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Antidepressive Agents, Tricyclic; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Primary Health Care; Recurrence; Risk Factors; Severity of Illness Index; Substance-Related Disorders; Taurine; Treatment Outcome | 2001 |
Drug treatments for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2002 |
Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats.
Topics: Acamprosate; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethanol; Male; Naltrexone; Rats; Rats, Wistar; Taurine; Temperance | 2003 |
Physicians' opinions about medications to treat alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Clinical Competence; Disulfiram; Health Care Surveys; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2003 |
New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Humans; Naltrexone; Taurine; Treatment Refusal | 2003 |
Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.
Topics: Acamprosate; Animals; Choice Behavior; Ethanol; Male; Memantine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Saccharin; Substance Withdrawal Syndrome; Sweetening Agents; Taurine | 2004 |
The mosaic of addiction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Addictive; Disease Models, Animal; Endorphins; Ethanol; Euphoria; Humans; Naltrexone; Receptors, Dopamine D2; Receptors, Opioid; Secondary Prevention; Taurine | 2004 |
Ask the doctor. I need to quit drinking, but don't think I can do it on my own. Can I use a drug like Antabuse even though I have heart disease?
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Contraindications; Disulfiram; Heart Diseases; Humans; Naltrexone; Taurine | 2004 |
Acamprosate campral for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Diarrhea; Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Taurine | 2005 |
[The pharmacologic treatment of the alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Resuscitative effect of a gamma-aminobutyric acid B receptor antagonist on gamma-hydroxybutyric acid mortality in mice.
Topics: Animals; Benzocycloheptenes; Bicuculline; Drug Overdose; Flumazenil; GABA Antagonists; gamma-Aminobutyric Acid; Male; Mice; Morpholines; Naltrexone; Neuroprotective Agents; Neurotransmitter Agents; Survival Rate; Taurine | 2005 |
A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment.
Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Secondary Prevention; Sex Characteristics; Taurine | 2005 |
Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.
Topics: Academies and Institutes; Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cooperative Behavior; Cross-Cultural Comparison; Disulfiram; Drug Approval; Drug Industry; Drugs, Investigational; Evidence-Based Medicine; Humans; Interprofessional Relations; Naltrexone; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Taurine | 2005 |
Drug treatment for alcoholism today.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Disulfiram; Fructose; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine; Topiramate | 2005 |
Choosing pharmacotherapies for the COMBINE Study--process and procedures: an investigational approach to combination pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Research Design; Taurine; Treatment Outcome | 2005 |
The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Guidelines as Topic; Health Personnel; Humans; Naltrexone; Narcotic Antagonists; Observer Variation; Surveys and Questionnaires; Taurine; Terminology as Topic | 2005 |
New alcohol abuse drugs emerging. Anti-craving meds are finally here to treat alcohol dependence, recognized as a disease of the brain.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine | 2005 |
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Female; Health Care Surveys; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 2006 |
The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Attitude to Health; Disulfiram; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychological Theory; Psychology; Psychotherapy; Taurine | 2006 |
Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Appetitive Behavior; Dose-Response Relationship, Drug; Drinking; Hunger; Injections, Intraperitoneal; Male; Mice; Mice, Inbred Strains; Naltrexone; Reinforcement Schedule; Taurine; Thirst | 2006 |
[Maintaining abstinence after alcohol detoxification].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ambulatory Care; Behavior Therapy; Clinical Protocols; Cognitive Behavioral Therapy; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Patient Care Planning; Psychoanalytic Therapy; Psychotherapy, Group; Psychotropic Drugs; Social Support; Taurine; Temperance | 2006 |
Extended-release intramuscular naltrexone: a viewpoint by Henry R Kranzler.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Taurine | 2006 |
Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2006 |
[Drugs against alcohol abuse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Drug Evaluation; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2006 |
Alcohol dependence and pharmacologic treatment. Introduction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Humans; Naltrexone; Taurine; United States | 2007 |
Schizophrenia and co-occurring substance use disorder.
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Humans; Ill-Housed Persons; Male; Naltrexone; Schizophrenia; Substance-Related Disorders; Taurine | 2007 |
Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Naltrexone; Nitriles; Receptors, Dopamine D3; Taurine; Tetrahydroisoquinolines | 2007 |
Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Genetic Predisposition to Disease; Germany; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychotherapy; Randomized Controlled Trials as Topic; Recurrence; Spain; Taurine; Treatment Outcome | 2008 |
New therapies for alcohol dependence open options for office-based treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family Practice; Fructose; Humans; Naltrexone; Taurine; Topiramate | 2007 |
A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration.
Topics: Acamprosate; Alcohol Deterrents; Animals; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Fluid; Frontal Lobe; Injections, Intraperitoneal; Male; Metabolic Clearance Rate; Microdialysis; Naltrexone; Rats; Rats, Long-Evans; Taurine | 2008 |
From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Receptors, Dopamine; Receptors, GABA; Receptors, Opioid; Taurine | 2008 |
Effects of naltrexone and acamprosate on alcohol-induced NGFI-A expression in mouse brain.
Topics: Acamprosate; Amygdala; Animals; Brain; Early Growth Response Protein 1; Ethanol; Male; Mice; Naltrexone; Taurine | 2008 |
Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Rats, Wistar; Taurine; Time Factors | 2008 |
[Pharmacotherapy of alcohol dependence].
Topics: Acamprosate; Adrenergic beta-Antagonists; Alcohol Deterrents; Alcoholism; Ambulatory Care; Anticonvulsants; Benzodiazepines; Chlormethiazole; Ethanol; Family Practice; Humans; Naltrexone; Patient Admission; Secondary Prevention; Substance Withdrawal Syndrome; Taurine | 2008 |
Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Therapy; Drug Therapy, Combination; Genetic Carrier Screening; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Prognosis; Psychotherapy; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Taurine; Treatment Outcome | 2008 |
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Delayed-Action Preparations; Disulfiram; Drug Costs; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Osteopathic Medicine; Physicians; Physicians, Family; Psychiatry; Taurine; United States | 2009 |
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Body Weight; Conditioning, Operant; Data Interpretation, Statistical; Male; Naltrexone; Rats; Rats, Long-Evans; Sucrose; Taste; Taurine | 2009 |
Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychotherapy; Taurine; Treatment Outcome | 2009 |
Treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate; Vitamins | 2009 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome | 2009 |
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome; United States | 2010 |
The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Diffusion of Innovation; Follow-Up Studies; Health Services Research; Humans; Naltrexone; Nitrosamines; Organizational Culture; Organizational Innovation; Substance Abuse Treatment Centers; Taurine; United States | 2010 |
Pharmacotherapies for alcoholism: the old and the new.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Disease Models, Animal; Disulfiram; Drug Design; Humans; Naltrexone; Narcotic Antagonists; Neuropeptides; Neuropharmacology; Neurotransmitter Agents; Receptors, Neurotransmitter; Taurine | 2010 |
Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Financing, Personal; Health Expenditures; Humans; Naltrexone; Patient Acceptance of Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Taurine; United States | 2010 |
Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
Topics: Acamprosate; Administration, Oral; Adult; Age Factors; Alcohol Deterrents; Alcoholism; Ambulatory Care; Comorbidity; Delayed-Action Preparations; Disulfiram; Drug Therapy, Combination; Drug Utilization; Female; Humans; Injections, Intramuscular; Male; Mental Disorders; Middle Aged; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sex Factors; Substance Abuse Treatment Centers; Taurine; United States; Veterans | 2010 |
The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
Topics: Acamprosate; Accidents, Traffic; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Costs and Cost Analysis; Crime; Health Services; Humans; Naltrexone; Taurine | 2010 |
Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Sex Characteristics; Taurine; Treatment Outcome | 2010 |
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Fructose; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Temperance; Time Factors; Topiramate; Treatment Outcome | 2010 |
Comparison of healthcare utilization among patients treated with alcoholism medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Female; Health Services; Health Status Indicators; Humans; Inpatients; Insurance Claim Review; Male; Middle Aged; Naltrexone; Narcotics; Propensity Score; Retrospective Studies; Taurine; United States | 2010 |
Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
Topics: Acamprosate; Alcohol Deterrents; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Substance Abuse Treatment Centers; Substance-Related Disorders; Taurine; United States | 2011 |
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Chi-Square Distribution; Databases, Factual; Disulfiram; Female; Health Care Costs; Health Services; Humans; Male; Naltrexone; Narcotic Antagonists; Propensity Score; Retrospective Studies; Statistics as Topic; Statistics, Nonparametric; Taurine; Treatment Outcome; United States | 2011 |
Pharmacogenetics of alcoholism: a clinical neuroscience perspective.
Topics: Acamprosate; Alcoholism; Alleles; Disulfiram; Genetic Markers; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Opioid, mu; Serotonin Plasma Membrane Transport Proteins; Taurine | 2012 |
Pharmacotherapy for adolescent alcohol use disorder.
Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Central Nervous System Stimulants; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Taurine | 2012 |
Cocaine reverses the naltrexone-induced reduction in operant ethanol self-administration: the effects on immediate-early gene expression in the rat prefrontal cortex.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Carrier Proteins; Cocaine; Conditioning, Operant; Cyclooxygenase 2; Dose-Response Relationship, Drug; Gene Expression; Genes, fos; Genes, Immediate-Early; Homer Scaffolding Proteins; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Prefrontal Cortex; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Self Administration; Taurine | 2012 |
Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Disulfiram; Drug Utilization; Female; Formularies as Topic; Health Care Surveys; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Preference; Practice Guidelines as Topic; Practice Patterns, Physicians'; Qualitative Research; Taurine; United States; United States Department of Veterans Affairs; Veterans Health | 2013 |
Neuropsychopharmacological actions of taurine.
Topics: Amino Acids; Animals; Cocaine; Conditioning, Psychological; Extracellular Space; Locomotion; Models, Biological; Naltrexone; Neostriatum; Nervous System; Oligopeptides; Psychotropic Drugs; Rats; Receptors, N-Methyl-D-Aspartate; Taurine | 2013 |
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Naltrexone; Patient Compliance; Patient Satisfaction; Taurine; Time Factors; Treatment Outcome | 2013 |
Review: In alcohol use disorders, acamprosate is more effective for inducing abstinence while naltrexone is more effective for reducing heavy drinking and craving.
Topics: Alcohol Deterrents; Alcohol-Related Disorders; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2013 |
[Drug therapy supports reduction of alcohol consumption].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Taurine | 2014 |
Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids.
Topics: Acamprosate; Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Bupropion; Dose-Response Relationship, Drug; Fructose; Indoles; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats, Wistar; Taurine; Tobacco Use Cessation Devices; Topiramate | 2016 |
Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT.
Topics: Acamprosate; Age Factors; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Combined Modality Therapy; Controlled Clinical Trials as Topic; Decision Trees; gamma-Glutamyltransferase; Germany; Goals; Humans; Logistic Models; Middle Aged; Naltrexone; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Taurine; Time Factors; Treatment Outcome; United States | 2014 |
Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Eating; Ethanol; Male; Naltrexone; Pregnanolone; Rats; Rats, Long-Evans; Self Administration; Taurine | 2015 |
[Acamprosate and naltrexone: similar efficacy for relapse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Taurine | 2014 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination; Humans; Insurance Coverage; Medicaid; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Taurine; United States | 2015 |
Association between a brief alcohol craving measure and drinking in the following week.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Taurine; United States | 2016 |
Access to Addiction Pharmacotherapy in Private Health Plans.
Topics: Acamprosate; Buprenorphine; Cost Sharing; Evidence-Based Practice; Formularies as Topic; Health Services Accessibility; Humans; Insurance, Health; Naltrexone; Substance-Related Disorders; Surveys and Questionnaires; Taurine; United States | 2016 |
National trends in alcohol pharmacotherapy: Findings from an Australian claims database.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Drug Administration Schedule; Female; Guideline Adherence; Humans; Insurance Claim Review; Male; Naltrexone; Patient Compliance; Retrospective Studies; Taurine; Temperance | 2016 |
Pharmacotherapy for Adults with Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2016 |
Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe.
Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Europe; Humans; Marketing; Naltrexone; Narcotic Antagonists; Perception; Practice Guidelines as Topic; Societies, Medical; Surveys and Questionnaires; Taurine; Treatment Outcome | 2016 |
Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Taurine; Topiramate; United States; United States Department of Veterans Affairs; Veterans; Young Adult | 2016 |
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Missouri; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Psychotherapy; Taurine | 2016 |
Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
Topics: Acamprosate; Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Marijuana Use; Middle Aged; Naltrexone; Narcotic Antagonists; Prognosis; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2017 |
Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Australia; Drug Prescriptions; Female; Health Services Accessibility; Healthcare Disparities; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Retrospective Studies; Social Class; Taurine; Vulnerable Populations; Young Adult | 2017 |
Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Interviews as Topic; Male; Naltrexone; Residential Treatment; Taurine; United States; United States Department of Veterans Affairs; Veterans | 2017 |
First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Naltrexone; Ontario; Population Surveillance; Retrospective Studies; Single-Payer System; Taurine; Young Adult | 2017 |
Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drinking Behavior; Female; Humans; Male; Naltrexone; Risk; Taurine; Treatment Outcome; United Kingdom; United States | 2017 |
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline | 2017 |
High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.
Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Darkness; Disease Models, Animal; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Naltrexone; Taurine | 2017 |
Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Naltrexone; Ontario; Taurine | 2023 |